Episode Overview

Title: Replay: This Jail in Rural Maine Is a Model for Treating Opioid Addiction
Podcast: The Opinions by New York Times Opinion
Date: August 27, 2025
Main Theme:
The episode explores a pioneering opioid addiction treatment program at the Somerset County Jail in rural Maine, focusing on the use of monthly injectable medication (Sublocade) over traditional daily treatments like Suboxone. Host Elaine O’Connor (director of Addiction Medicine at the jail) walks listeners through the program's inception, mechanics, and outcomes, highlighting the potential of jails as intervention points and the challenges posed by funding and stigma.

Key Discussion Points & Insights

1. Background: The Opioid Epidemic in Rural Maine

• Maine's opioid crisis: One of the highest rates of opioid use disorder in the nation, with especially acute problems among incarcerated populations.
• Elaine O’Connor’s perspective:
  • Jails present critical, often underutilized opportunities for addiction treatment.
  • Entry to jail can be a moment of heightened motivation for recovery.
• Quote:
  • “Jails are an incredible opportunity to help people enter recovery. It’s a time where motivation is often very high.” — Elaine O’Connor [01:10]

2. The Pilot Program: Sublocade Injections

• Medication-assisted therapy:
  • Traditional daily treatments (Methadone, Suboxone) are hard to deliver in jail settings.
  • Sublocade (once-a-month injection) is proposed as an alternative.
• How it works:
  • Sublocade is injected into the abdomen and dissolves slowly, maintaining steady opioid blockage for 28–44 days.
  • Advantage: Eliminates daily choice, which is vulnerable to relapse triggers.
• Greg Ellis (Physician Assistant), Jamie Van de Graaff (participant):
  • Jamie shares struggles with daily Suboxone: days when he’d skip the dose and relapse.
• Quote:
  • “The one transformative difference is really that Sublocade only needs to be injected once a month.” — Elaine O’Connor [03:31]

3. Inside the Treatment Process

• Administration:
  • Procedure explained—from alcohol prep to observing patients for band-aid diversion after injection.
  • Notable moment: After injection, patients feel a small bump, which reassures them the medication is present.
• Impact on experience:
  • Steady blood level reduces withdrawal and cravings.
• Quote:
  • “After we give the patient the Sublocade, we don’t need to see him again for another month ... Patients actually find the presence of the bump to some extent reassuring.” — Elaine O’Connor [05:49]

4. Personal Stories & Emotional Insights

• Jamie Van de Graaff’s story:

  • Started using heroin at 12, often introduced by family.
  • Repeated cycles of relapse due to life stress and medication lapses.
  • Overdosed multiple times; credits program with giving him a shot at normalcy and hope.

• Quotes:

  • “This is the first time you’ve been sober since you were a kiddo. How early did you start using substances?” — Elaine O’Connor [07:52]
  • “Not waking up, like, oh, when am I gonna get it?... I don’t have any cravings. And that’s the biggest thing we’re kind of fighting for.” — Jamie Van de Graaff [08:54]
  • “If I need to take this shot for the rest of my life, I will. For me, if it keeps me off drugs and alive, why not?” — Jamie Van de Graaff [09:29]

• Societal stigma:

  • O’Connor emphasizes no one aspires to addiction; criticizes public misconception that stopping is simply a matter of will.
  • Quote:
    • “I’ve never, ever met anyone who said, I want to grow up and be addicted to drugs and end up in jail.” — Elaine O’Connor [09:33]

5. Program Outcomes – Data and Results

• Pilot study:
  • Compared Sublocade recipients at Somerset to a control group on Suboxone in another rural jail.
  • Outcomes were superior for the injection group:
    • Nearly three times as likely to continue treatment post-release.
    • No deaths in Sublocade group within a year of release (vs. four in Suboxone group).
    • Reduction in medication diversion and side effects; patient preference for injection.
• Quote:
  • “We found that people treated with Sublocade were almost three times as likely to continue treatment when they leave the jail... Clearly, the most important finding was that we had no deaths in the people that were treated in the Sublocade pilot.” — Elaine O’Connor [11:01]

6. Barriers: Cost & Policy Challenges

• High financial costs:
  • Sublocade: $1,500–$1,700/month, 4x more expensive than pills.
  • Local counties must shoulder drug costs due to Medicaid exclusion for incarcerated individuals.
• Policy update on the horizon:
  • New Medicaid waiver may cover inmates for 90 days before release—implementation likely 1-2 years off.
• Economic argument:
  • Treating opioid use disorder in jail reduces recidivism and re-incarceration costs long-term.
• Quote:
  • “When people say, oh, it’s too much, why would we spend that much on any individual? I think about the obituaries of the four people that died from the other jail. And that’s the reason we do it.” — Elaine O’Connor [13:14]

Memorable Moments and Quotes (with Timestamps)

• [01:10] Elaine O’Connor: “Jails are an incredible opportunity to help people enter recovery. It’s a time where motivation is often very high.”

• [03:31] Elaine O’Connor: “The one transformative difference is really that Sublocade only needs to be injected once a month.”

• [04:10] Jamie Van de Graaff: “There’d be times I’d wake up and having a bad day or a crisis and I’d say, hey, I don’t want to take my Suboxone today. And then I’d switch back to using heroin.”

• [08:54] Jamie Van de Graaff: “Not waking up, like, oh, when am I gonna get it? ... I don’t have any cravings. And that’s the biggest thing we’re kind of fighting for.”

• [09:33] Elaine O’Connor: “I’ve never, ever met anyone who said, I want to grow up and be addicted to drugs and end up in jail.”

• [11:01] Elaine O’Connor: “People treated with Sublocade were almost three times as likely to continue treatment when they leave the jail... We had no deaths in the people that were treated in the Sublocade pilot.”

• [13:14] Elaine O’Connor: “I think about the obituaries of the four people that died from the other jail. And that’s the reason we do it.”

Important Segments / Timestamps

• Introduction and Maine opioid context: [00:48–02:45]
• Medication details and pilot rationale: [02:45–04:46]
• Jamie’s personal story / Inmate experiences: [04:46–09:33]
• Outcome data and pilot results: [09:33–11:30]
• Barriers to expansion and policy critique: [11:30–13:14]

Tone and Takeaway

The episode is empathetic, hopeful, and sober about policy hurdles. The speakers use clear, relatable language, centering patient dignity and emphasizing that treating opioid use disorder is a matter of life, death, and social responsibility. The Somerset County Jail model shows transformative potential for addiction treatment nationwide—if challenges of cost and policy can be addressed.